Research outlook

Where triple-negative breast cancer treatment is heading

Triple-negative breast cancer · Updated Nov 15, 2026

Triple-negative breast cancer (TNBC) makes up about 1 in 7 breast cancers. It lacks the three receptors that hormone and HER2 drugs target, so chemotherapy, immunotherapy and antibody-drug conjugates (antibodies that carry chemotherapy into cancer cells) are the main tools. Early TNBC is treated with chemotherapy plus pembrolizumab before and after surgery. In 2025 and 2026, TROP2 antibody-drug conjugates beat chemotherapy as first treatment for advanced disease, and trials are now testing them after surgery.

  1. Now

    Nov 2026

    Antibody-drug conjugates move to first lineHappened 11.2 months without progression

    Sacituzumab govitecan plus pembrolizumab (11.2 vs 7.8 months) and Dato-DXd (23.7 vs 18.7 months survival) beat chemotherapy-based first treatment.

    11.2: months without progression, vs 7.8 with chemo plus pembrolizumab.

    Pembrolizumab around surgery saves livesHappened 86.6% alive at 5 years

    Final KEYNOTE-522 results: 86.6% alive at 5 years vs 81.7%. A trial of atezolizumab instead did not clearly help.

    86.6%: alive at 5 years, vs 81.7% without pembrolizumab.

    Olaparib for inherited BRCA mutationsHappened 89.8% alive at 4 years

    A year of olaparib after treatment raised 4-year survival to 89.8% vs 86.4%.

    89.8%: alive at 4 years, vs 86.4% with placebo.

  2. 6 months

    by May 2027

    Pembrolizumab for leftover cancerLikely

    SWOG S1418 (1,195 people) tests a year of pembrolizumab after surgery when cancer remained; its main analysis was due August 2026.

    Sacituzumab govitecan after surgeryPossible 9.7 months without progression (advanced)

    GBG's SASCIA (1,332 people) compares it with standard chemotherapy for leftover cancer; due March 2027.

    9.7: months without progression in advanced disease, vs 6.9 with chemotherapy.

  3. 12 months

    by Nov 2027

    Antibody-drug conjugates after surgeryPossible

    ASCENT-05 (Gilead, due June 2027) and TROPION-Breast03 (AstraZeneca, due September 2027) test them for cancer left after pre-surgery treatment.

    Dato-DXd with immunotherapy firstPossible 23.7 months median survival (Dato-DXd alone)

    TROPION-Breast05 (625 people) tests Dato-DXd with durvalumab for PD-L1-positive advanced TNBC; due July 2027.

    23.7: months median survival with Dato-DXd alone, vs 18.7.

  4. 3 years

    by late 2029

    A new pre-surgery regimenPossible

    TROPION-Breast04 (1,902 people) compares Dato-DXd plus durvalumab with the KEYNOTE-522 regimen; due November 2028. A win could reduce chemotherapy before surgery.

    An EGFR-HER3 antibody-drug conjugatePossible

    Bristol Myers Squibb's trial (600 people) compares iza-bren with chemotherapy in previously treated TNBC; due March 2028.

  5. 5 years

    by late 2031

    PD-L1 and VEGF bispecificsLong shot 73.8% tumors shrank (early trial)

    BioNTech's ROSETTA Breast-01 (558 people) tests pumitamig with chemotherapy; due December 2029.

    73.8%: of tumors shrank in an early trial.

    Sac-TMT across stagesPossible 6.7 months without progression (later line)

    Merck's trials test sac-TMT first line (due May 2030) and after surgery with pembrolizumab (due December 2030).

    6.7: months without progression with sac-TMT, vs 2.5 with chemotherapy.

Happened Likely Possible Long shot

The research paths

Heating up

TROP2 antibody-drug conjugates

11.2 months without progression
Details and 7 trialsHide
Maturing

Fine-tuning immunotherapy

86.6% alive at 5 years
Details and 3 trialsHide
Early

New targets and bispecifics

73.8% tumors shrank
Details and 2 trialsHide

Antibodies that block PD-L1 and VEGF together, and conjugates aimed at EGFR and HER3.

WatchROSETTA Breast-01.

Borrowed from other cancers

From Lung cancer

Pumitamig

Phase 3

A PD-L1 and VEGF bispecific antibody also in phase 3 for small cell and non-small cell lung cancer.

From EGFR-mutant lung cancer

Izalontamab brengitecan

Phase 3

An EGFR-HER3 antibody-drug conjugate first developed in lung and esophageal cancer.

From Ovarian cancer

Olaparib

Approved

A PARP inhibitor first approved for BRCA-mutated ovarian cancer, now used after treatment for BRCA-mutated breast cancer.

Open to join now

See every recruiting TNBC trial →

When the trials finish

Completion dates the trials registered. Results usually follow 3 to 12 months later.

2026202720282029203020312032Today
Sacituzumab govitecan after surgery (SASCIA)TROP2 antibody-drug conjugates
Mar 2027
Iza-bren vs chemotherapyNew targets and bispecifics
Mar 2028
Nov 2028
Dec 2029
Sac-TMT, first lineTROP2 antibody-drug conjugates
May 2030
Sac-TMT plus pembrolizumab after surgeryTROP2 antibody-drug conjugates
Dec 2030

What just happened

Pumitamig plus chemo shrinks most tumors in early trial

Lancet Oncology.

Atezolizumab before surgery misses main goal

NSABP B-59/GeparDouze, Nature Medicine.

Dato-DXd extends survival in first-line TNBC

TROPION-Breast02, Annals of Oncology.

Sacituzumab govitecan plus pembrolizumab beats chemo plus pembrolizumab

ASCENT-04, NEJM.

Standard treatment today

How to read this page, and sourcesHow to read this page, and sources

See TNBC trials recruiting now →

Last reviewed 2026-11-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.